RT Journal Article SR Electronic T1 Nine Neuroimaging-AI Endophenotypes Unravel Disease Heterogeneity and Partial Overlap across Four Brain Disorders: A Dimensional Neuroanatomical Representation JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.08.16.23294179 DO 10.1101/2023.08.16.23294179 A1 Wen, Junhao A1 Skampardoni, Ioanna A1 Tian, Ye Ella A1 Yang, Zhijian A1 Cui, Yuhan A1 Erus, Guray A1 Hwang, Gyujoon A1 Varol, Erdem A1 Boquet-Pujadas, Aleix A1 Chand, Ganesh B. A1 Nasrallah, Ilya A1 Satterthwaite, Theodore A1 Shou, Haochang A1 Shen, Li A1 Toga, Arthur W. A1 Zalesky, Andrew A1 Davatzikos, Christos YR 2024 UL http://medrxiv.org/content/early/2024/09/25/2023.08.16.23294179.abstract AB Disease heterogeneity poses a significant challenge for precision diagnostics. Recent work leveraging artificial intelligence has offered promise to dissect this heterogeneity by identifying complex intermediate brain phenotypes, herein called dimensional neuroimaging endophenotypes (DNEs). We advance the argument that these DNEs capture the degree of expression of respective neuroanatomical patterns measured, offering a dimensional neuroanatomical representation for studying disease heterogeneity and similarities of neurologic and neuropsychiatric diseases. We investigate the presence of nine such DNEs derived from independent yet harmonized studies on Alzheimer’s disease (AD1-2)1, autism spectrum disorder (ASD1-3)2, late-life depression (LLD1-2)3, and schizophrenia (SCZ1-2)4, in the general population of 39,178 participants in the UK Biobank study. Phenome-wide associations revealed prominent associations between the nine DNEs and phenotypes related to the brain and other human organ systems. This phenotypic landscape aligns with the SNP-phenotype genome-wide associations, revealing 31 genomic loci associated with the nine DNEs (Bonferroni corrected P- value < 5x10-8/9). The DNEs exhibited significant genetic correlations, colocalization, and causal relationships with multiple human organ systems and chronic diseases. A causal effect (odds ratio=1.25 [1.11, 1.40], P-value=8.72x10-4) was established from AD2, characterized by focal medial temporal lobe atrophy, to AD. The nine DNEs, along with their polygenic risk scores, significantly enhanced the predictive accuracy for 14 systemic disease categories, particularly for conditions related to mental health and the central nervous system, as well as mortality outcomes. These findings underscore the potential of the nine DNEs to capture the expression of disease-related brain phenotypes in individuals of the general population and to relate such measures with genetics, lifestyle factors, and chronic diseases. All results are publicly available at https://labs-laboratory.com/medicine/.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe gratefully acknowledge the support of the iSTAGING consortium, funded by the National Institute on Aging through grant RF1 AG054409 at the University of Pennsylvania (CD). We also acknowledge the funding provided by the National Institute of Biomedical Imaging and Bioengineering at the University of Southern California through grant 5P41EB015922-25 (AT). Additionally, we acknowledge the funding program from the Rebecca L. Cooper Foundation at the University of Melbourne (AZ).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study used only the UK Biobank data under the application numbers: 35148 and 60698. No specific additional IRBs are required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll GWAS summary statistics are publicly available at: https://labs-laboratory.com/medicine/ https://labs-laboratory.com/medicine/